Clinical Trial

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Protocol Amendment History 49 amendments
This ClinicalTrials.gov record has been amended 49 times since 2023-11-01; most recent amendment 2026-04-07.
Trial Details
NCT Number NCT06121297
Lead Sponsor Cabaletta Bio
Conditions Systemic Lupus Erythematosus, Lupus Nephritis
Enrollment 28 participants
Start Date 2024-02-16
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-09